Nestle invests in microbiome-based diagnostics venture

ZURICH (Reuters) - Food group Nestle's health science business is investing 20 million euros ($22.8 million) in a joint venture with pharma and diagnostics company Enterome SA to develop microbiome-based diagnostics for inflammatory bowel and liver diseases, Enterome said on Tuesday.